NCT03934840 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03934840
Title	Phase 2 of Carbo, Taxel and Abi in Metastatic Castration Prostate Cancer
Recruitment	Active, not recruiting
Gender	male
Phase	Phase II
Variant Requirements	No
Sponsors	Masonic Cancer Center, University of Minnesota
Indications	prostate cancer
Therapies	Abiraterone + Cabazitaxel + Carboplatin + Prednisone
Age Groups:	senior \| adult
Covered Countries	USA

Filter rows:

Showing 1 to 8 of 8 entries

Facility	City	State	Zip	Country	Details
Comprehensive Cancer Centers of Nevada	Las Vegas	Nevada	89169	United States	Details
Lifespan Cancer Institute	Providence	Rhode Island	02903	United States	Details
Masonic Cancer Center at University of Minnesota	Minneapolis	Minnesota	55455	United States	Details
Mayo Clinic Arizona	Phoenix	Arizona	85054	United States	Details
Northwestern University	Chicago	Illinois	60611	United States	Details
Thomas Jeferson University	Philadelphia	Pennsylvania	19107	United States	Details
Tulane University	New Orleans	Louisiana	70112	United States	Details
University of Chicago	Chicago	Illinois	60637	United States	Details

Showing 1 to 8 of 8 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT03934840Clinical Trial Detail